Summary
53 / 100 · Bulios Score
What speaks for it
- Out of every 100 AUD of revenue, 12 AUD is left as free cash.
- It could repay all its net debt from 0.1 years of operating profit.
What to watch
- It pays out more in dividends than it earns: 156% of profit.
- The share price is above the Bulios Fair Price.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensivePrice against the Bulios Fair Price
P/E against the industry (Medical - Devices)
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 56.8 AUD for 1 AUD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (AUD)
Diluted EPS (AUD)
- Analyst estimate
Revenue grew by 9.5% a year over 5 years. Over the last 3 years it grew by 6.3% a year. For the next fiscal year analysts expect revenue to grow by 5.1%.
Growth in detailDoes it make money?
Income figures for the last 12 months are not available.
Profitability in detailIs it financially healthy?
Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.74%
- Paid out of profit
- 156%
- Raised in a row
- 4 years
You receive $1.23 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Today's price within the analysts' price targets
The average target of $117 is 157% above today's price.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.